Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Delayed neutrophil recovery following BCMA CAR-T therapy in Duffy-null myeloma does not impact severe infections or survival.
Avigan ZM, Bodnar S, Pan D, Catlett JL 2nd, Richter J, Sanchez LJ, Rodriguez C, Rossi AC, Richard S, Jagannath S, Cho HJ, Parekh S, Thibaud S. Avigan ZM, et al. Among authors: thibaud s. Blood Adv. 2024 Oct 9:bloodadvances.2024014255. doi: 10.1182/bloodadvances.2024014255. Online ahead of print. Blood Adv. 2024. PMID: 39383457 No abstract available.
Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes.
Thibaud S, Subaran RL, Newman S, Lagana A, Melnekoff DT, Bodnar S, Ram M, Soens Z, Genthe W, Brander T, Mouhieddine TH, Van Oekelen O, Houldsworth J, Cho HJ, Richard S, Richter J, Rodriguez C, Rossi A, Sanchez L, Chari A, Moshier E, Jagannath S, Parekh S, Onel K. Thibaud S, et al. Blood Cancer Discov. 2024 Nov 1;5(6):428-441. doi: 10.1158/2643-3230.BCD-23-0208. Blood Cancer Discov. 2024. PMID: 39283238 Free PMC article.
Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma.
Mejia Saldarriaga M, Pan D, Unkenholz C, Mouhieddine TH, Velez-Hernandez JE, Engles K, Fein JA, Monge J, Rosenbaum C, Pearse R, Jayabalan D, Gordillo C, Chan HT, Yamshon S, Thibaud S, Mapara M, Inghirami G, Lentzsch S, Reshef R, Rossi A, Parekh S, Jagannath S, Richard S, Niesvizky R, Bustoros M. Mejia Saldarriaga M, et al. Among authors: thibaud s. Blood Adv. 2024 Aug 13;8(15):3859-3869. doi: 10.1182/bloodadvances.2023012470. Blood Adv. 2024. PMID: 38776397 Free PMC article.
Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups.
Shah UA, Moshier E, Derkach A, Huang Y, Mailankody S, Tan CR, Maclachlan K, Hultcrantz M, Korde N, Hassoun H, Thibaud S, Sanchez L, Rodriguez C, Richard S, Richter J, Rossi A, Cho HJ, Lesokhin A, Chari A, Usmani SZ, Jagannath S, Parekh S, Gallagher EJ. Shah UA, et al. Among authors: thibaud s. Blood Adv. 2024 Jan 9;8(1):236-247. doi: 10.1182/bloodadvances.2023010815. Blood Adv. 2024. PMID: 37772981 Free PMC article.
IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies.
Lancman G, Parsa K, Kotlarz K, Avery L, Lurie A, Lieberman-Cribbin A, Cho HJ, Parekh SS, Richard S, Richter J, Rodriguez C, Rossi A, Sanchez LJ, Thibaud S, Jagannath S, Chari A. Lancman G, et al. Among authors: thibaud s. Blood Cancer Discov. 2023 Nov 1;4(6):440-451. doi: 10.1158/2643-3230.BCD-23-0049. Blood Cancer Discov. 2023. PMID: 37769148 Free PMC article.
Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy.
Van Oekelen O, Nath K, Mouhieddine TH, Farzana T, Aleman A, Melnekoff DT, Ghodke-Puranik Y, Shah GL, Lesokhin A, Giralt S, Thibaud S, Rossi A, Rodriguez C, Sanchez L, Richter J, Richard S, Cho HJ, Chari A, Usmani SZ, Jagannath S, Shah UA, Mailankody S, Parekh S. Van Oekelen O, et al. Among authors: thibaud s. Blood. 2023 Feb 16;141(7):756-765. doi: 10.1182/blood.2022017848. Blood. 2023. PMID: 36327160 Free PMC article.
Bridging advanced myeloma patients to subsequent treatments and clinical trials with classical chemotherapy and stem cell support.
Mouhieddine TH, Moshier E, Thibaud S, Puliafito B, Rattu M, Jakubowski R, Sanchez L, Rossi A, Rodriguez C, Richard S, Cho HJ, Parekh S, Chari A, Steinberg A, Richter J. Mouhieddine TH, et al. Among authors: thibaud s. Bone Marrow Transplant. 2023 Jan;58(1):80-86. doi: 10.1038/s41409-022-01848-7. Epub 2022 Oct 19. Bone Marrow Transplant. 2023. PMID: 36261708
Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma.
Mouhieddine TH, Van Oekelen O, Melnekoff DT, Li J, Ghodke-Puranik Y, Lancman G, Thibaud S, Pan D, Rajeeve S, Agte S, Aleman A, Sanchez L, Richard S, Rossi A, Richter J, Cho HJ, Rodriguez C, Lagana A, Moshier E, Chari A, Jagannath S, Parekh S. Mouhieddine TH, et al. Among authors: thibaud s. Blood Adv. 2023 Mar 28;7(6):1056-1064. doi: 10.1182/bloodadvances.2022007923. Blood Adv. 2023. PMID: 36018226 Free PMC article. Clinical Trial.
24 results